• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A biotech company developing and commercializing vaccines for infectious diseases with major unmet needs

VAL_Report_2018_Teaser_Website_Home_800x400_190320.jpg

Download 2018 Valneva Annual Business Report


June 12, 2019
Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate
Read more

— Stock information

@valnevase




-
— June 11, 2019
Valneva to Present Lyme Disease and Chikungunya Updates at R&D Investor Day in New York City on July 9th

Read more
— Financial Calendar
Valneva Shareholders' Meeting
June 27, 2019, Paris
Availability of Documentation
Read more


See all dates


— Vienna Stock Exchange Delisting /
Delisting von der Wiener Börse

Shareholder information
Informationen für Aktionäre


AKTUELLES

News in German


 
VALNEVA
LIBRARY


Images, presentations and videos

JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Company Video

– Upcoming conferences


Raymond James Sciences & Medtech Conference 
June 18-19, 2019, New York

France Biotech Health Tech Investor Day
June 24-25, 2019, Paris

Valneva R&D Investor Day
July 9, 2019, New York City


Please update your browser...